|
||||
She is the protagonist of the epic breast cancer survivor story. She exists in many iterations; in magazines, advertisements, news stories, and awareness events. She is a superwoman who courageously, passionately, and aggressively battles disease. She faces tremendous difficulties. With style and optimism, she learns from her experience, is transformed, and shares lessons learned. She is the SHE-RO, the triumphant . . . → Read More: The She-ro Lani Horn, a.k.a. Chemobabe Pink Ribbon Blues is honored to share a recent post from blogger, Lani Horn, who writes under the name Chemobabe. She is a social scientist in her “regular life” and created ChemoBabe as a persona who has “enough spunk and edge to get smacked down” by treatment and “stand back up ready to fight some . . . → Read More: Attention! [by Chemobabe] Photo by Astrid Stawiarz for The Wall Street Journal The fury over Komen’s official responses to the trademark debacle continues to mount as individuals, breast cancer advocates, journalists, bloggers, and the diagnosed raise numerous questions about Komen’s trademark policing, hubris, and financial allocations. Despite an ambiguous admission on the Nightly News with Brian Williams that Komen may have . . . → Read More: Komen’s Leadership In Question Sarah Horton, author of Being Sarah, a true story about choice, control and breast cancer, is today’s Pink Ribbon Blues contributor. Photo Credit: Karen Choudhary I was diagnosed with breast cancer in February 2007. Nearly four years ago. And four years of breast cancer treatment is a lot of hospitals, doctors, and blood tests. A lot. And during . . . → Read More: There Is More That Unites Us Peggy Orenstein, author of forthcoming book Cindarella Ate My Daughter, wrote a compelling article for The New York Times Magazine (Nov. 12, 2010) addressing contemporary efforts to make breast cancer “sexy” for an upbeat and stylized cancer marketplace. In Think About Pink, Orenstein critiques the “I ❤ Boobies” and “Save the Ta-tas” campaigns that detract from the truth about breast . . . → Read More: NY Times Magazine’s, “Think About Pink” The Dallas Morning News published an article yesterday by Kim Horner exploring the growing concern about pinking and pinkwashing. In “Merchandise tie-ins to breast cancer awareness have some seeing red over all that pink,” Horner speaks to those in support of, and those concerned about, all the pink. From pink rubber duckies to Smith & Wesson handguns with pink grip, . . . → Read More: “Seeing Red Over All That Pink” According to an article in The Vindicator by Kristine Gill, Susan G. Komen for the Cure stands firm that there is not enough pink. Carrie Glasscock, manager of corporate relations, states: “There’s not enough pink when every 69 seconds a woman is diagnosed with breast cancer around the world. Women are still dying from this disease.” Similarly, a . . . → Read More: Is Any Awareness Good Awareness? Indeed. You can have have virtual breast cancer, wear pink t-shirts, attend pink ribbon fund raising events, and even go to a support group. I’m speechless. Luckily, Anna Rachnel who writes The Cancer Culture Chronicles is not. What follows is Rachnel’s post about second life, titled “Virtual Breast Cancer.” — Virtual Breast Cancer by Anna Rachnel (October 22, 2010) . . . → Read More: Breast Cancer Avatars on Second Life? “Cancer charities which work with less glamorous cancers, bowel, lung, pancreatic for example, let alone charities working with distinctly unfashionable diseases…mental health charities and Alzheimers… envy the ease with which consumers spend on pink products, though some cancer charities may welcome the ‘trickle down’ effect.” –comment to The New York Times article Pink Ribbon Fatigue What is it . . . → Read More: Unfashionable Diseases and Less Glamorous Cancers |
"women urged to get screened because it might save their lives. But that’s only 1 possible outcome, and it’s the least likely one" @cragcrest cutt.ly/jei8WJr 
 |
|||
| Copyright © Gayle Sulik 2026 Pink Ribbon Blues - All Rights Reserved - Images on this site are used for the express purposes of commentary and criticism under the fair use doctrine. | ||||
